Who
Bhaskar Chaudhuri
Director
Company insider
Files Form 4 as: Director, Tarsus Pharmaceuticals; Director, Arcutis Biotherapeutics; Director, Teligent; Director, Corium International; President, Valeant Pharmaceuticals International.
In numbers
- Trades disclosed
- 100
- Buys
- 11
- Sells
- 10
- Bought
- $507K
- Sold
- $2.1M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 10 Mar 2009
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,954 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,954 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,954 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,954 | filing |
| 13 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,350 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,350 | filing |
| 12 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,540 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,954 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,568 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —7,609 at $0.00 | filing |
| 24 Jun 2024filed 25 Jun 2024 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,350 at $0.00 | filing |
| 24 Jun 2024filed 25 Jun 2024 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,350 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,052 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —10,139 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,350 at $0.00 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Bhaskar Chaudhuri; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.